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Abstract
Corticotropin releasing hormone (CRH) produces age-dependent limbic seizures in the infant rat.
Both the phenotype and the neuroanatomic matrix of CRH-induced seizures resemble the seizures
induced by the rigid glutamate analogue, kainic acid (KA), and by rapid amygdala kindling. The
experiments described in this study tested the hypothesis that the in vivo proconvulsant effects of
CRH require activation of ionotropic glutamate receptors. Non-competitive (+MK-801) or
competitive (CGP-39551) antagonists of N-methyl-D-aspartate (NMDA) receptors decreased or
eliminated the motor effects of CRH, but electrographic CRH-induced seizures were unaffected.
Administration of CRH antagonists did not affect the acquisition or the maintenance of rapid
kindling, which are mediated by NMDA and α-amino-3-hydroxy-5-methyl-isoxazole-4-propionate
(AMPA) receptor activation, respectively. CRH receptor blockers failed to alter the latency or
duration of seizures induced by activation of KA receptors, and threshold doses of CRH and KA
had additive effects. CRH given repeatedly decreased the convulsant threshold dose of KA,
probably via injury to hippocampal neurons. These results suggest that CRH and glutamate
increase neuronal excitability via independent mechanisms. Because the proconvulsant effects of
CRH are highly specific to the developmental period, glutamate-receptor-independent, CRH-
receptor mediated excitation may account for some of the enhanced susceptibility to seizures
during this period.
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1. Introduction
Corticotropin releasing hormone (CRH) is the cardinal central nervous system transducer of
stressful stimuli [43]. The limbic system, particularly the amygdala and hippocampus, are
rich in neuronal populations that either synthesize CRH or possess CRH receptors [3,14,42].
In the majority of neuronal circuits studied, CRH functions as an excitatory neuromodulator
[2,15]. During the second week of life in the rat, picomolar amounts of CRH induce severe
and prolonged seizures within minutes [10]. Furthermore, repeated administration of CRH
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doses (150 × 10−12 mole), which result in limbic status epilepticus, leads to excitotoxic
injury in select hippocampal and amygdala neurons in the infant rat [9].
CRH induces phenotypic ‘limbic seizures’. These consist of unstoppable oral automatisms,
wet dog shakes (WDS) and clonus [10,15]. These seizures resemble limbic seizures induced
by activation of the glutamate receptor family, for example, by the prototypical convulsant,
kainic acid (KA) [28]. Using depth-electrode mapping, CRH-induced seizures in the
immature rat were shown to originate in the amygdala and spread to the hippocampus and
neocortex [8]. The precise excitatory mechanisms by which CRH results in seizures have
not been fully determined. In particular, the requirement for activation of specific glutamate
receptor types in CRH-induced seizures has not been elucidated.
The purpose of the series of experiments reported here was to investigate potential
interactions between CRH and activation of discrete types of ionotropic glutamate receptors.
Several experimental paradigms were used for this purpose: (a) we studied the effects of
blocking N-methyl-D-aspartate (NMDA) type glutamate receptors on the behavioral and
electrographic aspects of CRH induced seizures in the immature rat. (b) we examined
whether blocking CRH receptors affected the latency or the duration of seizures induced by
activation of ionotropic glutamate receptors, using the prototypical convulsant KA. (c) we
determined potential interactions of glutamate and CRH receptor activation by using
threshold doses of both agents. (d) we evaluated the effects of CRH antagonists on functions
considered to require activation of NMDA and non-NMDA glutamate receptors, i.e., the
acquisition and maintenance of kindling, respectively [25,32].
2. Materials and methods
2.1. Drugs and chemicals
CRH and the CRH antagonist (9–41)-α-helical-CRH were purchased from Bachem
(Torrance, CA). KA and (+)MK-801 were purchased from Sigma (St. Louis, MO), and
CGP-39551 was a gift from Dr. M. Baudry, University of Southern California. Because of
the known variation in seizure severity and duration induced by different batches or
dilutions of KA, the drug was dissolved in a stock solution of 10 mg/kg, which was
aliquoted and kept frozen. Working solutions of 1 mg/ml were prepared freshly.
2.2. Animals
About 180 infant rats (postnatal days 10–12) were used. Pups were offspring of time-
pregnant, Sprague–Dawley rats (Zivic-Miller, Zelienople, PA). Pups were born in our
federally-approved animal facility, kept on a 12 h light/dark cycle and dams given access to
unlimited food and water. Cages were monitored for presence of pups every 12 h, and the
day of birth was considered day 0. Litters were culled to 12 pups and mixed among
experimental groups, so that each experiment consisted of groups matched for age. Cages
were maintained in a quiet, non-crowded room, and were undisturbed for 24 h prior to
experiments. All experiments were conducted in the morning, to avoid potential diurnal
variability in endogenous CRH content [45] or seizure susceptibility [35]. All experiments
were carried out according to NIH guidelines for the care of experimental animals and were
approved by the institutional animal care committee.
2.3. Surgical procedures and drug administration
For administration of CRH and the CRH antagonist, pups were implanted with lateral
cerebral ventricle (i.c.v.) cannulae [10], since CRH and the peptide CRH antagonists do not
cross the blood brain barrier. For electroencephalographic (EEG) recording and for kindling,
pups were equipped, in addition, with depth electrodes 24 h prior to experiments. The
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surgical procedures, including the age-specific stereotaxic coordinates for the amygdaloid
complex and for the dorsal hippocampus developed for the Sprague–Dawley rat pup, have
been described in detail elsewhere [6,7]. Briefly, electrodes were implanted under halothane
anaesthesia, using an infant-rat stereotaxic apparatus (Kopf, Tujunga, CA). Bipolar twisted
wire electrodes, (Plastics One, Roanoke, VA) with a wire diameter of 0.1–0.15 mm and
vertical inter-tip distance of 0.5–1.0 mm were inserted through a burr-hole and aimed at the
basolateral nucleus of the amygdala (for monitoring of CRH-induced seizures and kindling),
hippocampus (for KA- and CRH-induced seizures), or cortex (for KA-induced seizures).
Electrodes were anchored to the skull with an acrylic cement ‘cap’ attached to one or two
screws. Cannulae and electrode positions were verified after the experiments in all animals.
Brain growth during the 2 days of the experiments results in minimal (~ 0.08 mm) anterior–
posterior shift of cannulae and electrodes relative to bregma [37], but this has not been a
problem because both lateral ventricles and amygdala extend for > 1 mm on each side of the
cannula in the anterior–posterior axis.
CRH and the CRH-antagonist were infused i.c.v. to freely moving pups maintained
euthermic on a warming pad. The peptides were infused in a volume of 1–2 µl via the
chronic cannula using a micro-infusion pump and a Hamilton syringe attached to flexible
tubing. Cannula-carrying control animals were given a dye vehicle [8,9]. KA and the
selective glutamate receptor antagonists, which are known to cross the blood brain barrier,
were injected into the peritoneal cavity (i.p.) at a volume of 1.5–2 µl/g, and control animals
received the same volume of vehicle.
2.4. Parameters of behavioral seizure evaluation
Subsequent to CRH or KA administration, seizure latency and duration were monitored:
animals were scored for behavioral limbic seizures occurring during 5-min epochs for the
180 min subsequent to drug administration [10]. For kindling, a behavioral scale [7] has
been modified from Haas et al. [18]. Significant behavioral overlap between the behavioral
phenomena of CRH-induced seizures, rapid amygdala kindling and KA-induced seizures
were evident, as shown in Table 1.
2.5. EEG monitoring
For each treatment, a group of rat pups (n ≥ 4) was subjected to depth electrode
implantation, and the presence and location of epileptic discharges associated with CRH-,
KA- and kindling-induced seizures was monitored by EEG, as described in detail elsewhere
[6,7,10].
2.6. Experimental design
2.6.1. Experiment I—effect of NMDA-type receptor antagonists on CRH-
induced seizures—For this experiment, a moderate CRH dose (150 × 10−12 mole, about
0.05 µg/g body weight) was chosen, to result in seizures lasting for approximately 3 h [8].
The non-competitive NMDA receptor blocker, (+)MK-801 (0.2 and 1 mg/kg) and the
competitive antagonist CGP-39551 (3–30 mg/kg) were administered 40 min prior to CRH
infusion. The higher (+)MK-801 dose (1 mg/kg) resulted in very abnormal behavior (pups
appeared ill and unable to ambulate, occasionally with stiff tails) and EEG pattern.
Therefore, the data shown resulted from experiments in which the lower dose was used. For
CGP-39551, the highest dose utilized (30 mg/kg), also resulted in abnormal behavior and
EEG tracings. Therefore, a maximal dose of 10 mg/kg, shown to be effective as a
neuroprotectant after KA administration [44], was used for the EEG recordings. Fifty infant
rats were assigned to receive CRH alone or CRH after pre-treatment with the NMDA
receptor antagonists. Control groups consisted of pups receiving an NMDA antagonist only,
as well as cannula-carrying animals receiving vehicle. For all groups, the latency to onset
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and the duration of CRH-induced behavioral seizures was recorded. An additional set of
animals was monitored for the effects of the NMDA antagonists on CRH-induced EEG
epileptiform discharges, as noted above.
2.6.2. Experiment II—establishment of the threshold convulsant dose of KA
and validation of the EEG correlates of the behavioral seizures—Increasing
doses of KA were administered to groups (n = 3 to 12) of 10-day-old rats via i.p. injections.
KA doses ranged from 0.2 to 1 mg/kg, based on pilot data, to determine a threshold dose
capable of inducing automatisms and limbic seizures. Controls were injected in the same
mannner with equal volumes of vehicle. Following injections, the latency to onset and the
duration of seizures were recorded.
2.6.3. Experiment III—effect of CRH antagonist on KA induced seizures—The
competitive non-selective blocker of CRH receptors, (9–41)-α-helical CRH (1320 × 10−12
mole), was administered i.c.v. to the experimental group (n = 14) 30–40 min prior to KA
administration. This timing was based on the previously established time course for the
actions of this antagonist, and the antagonist dose was chosen based on its ability to
attenuate or abolish seizures induced by moderate doses of CRH [4,10]. Both the control (n
= 8) and experimental groups of infant rats received a moderate dose of KA for this age
group (1 mg/kg). An additional control group (n = 5) received the CRH antagonist alone.
For EEG, a separate group (n = 4) was implanted with bipolar electrodes aimed at the dorsal
hippocampus and cortex, to correlate behavioral KA-induced seizures with epileptic
discharges.
2.6.4. Experiment IV—does co-administration of threshold doses of CRH and
KA produce additive or synergistic effects?—Based on the results of experiment II,
a threshold i.p. dose of KA (0.2 mg/kg) was administered to the experimental group (n = 9)
30 min prior to i.c.v. infusion of a threshold CRH dose (22.5–30 × 10−12 mole) [10]. The
duration and severity of the resulting seizures were compared to those produced by each
agent alone in litter-mate controls (n = 8 each for KA and CRH).
2.6.5. Experiment V—effect of repeated CRH administration on the convulsant
threshold dose of KA—Based on previous experiments showing that four infusions of
CRH over 2 days led to excitotoxicity 16 h later [9], the effects of this regimen on the
threshold dose of KA was determined. CRH (150 × 10−12 mole) was infused i.c.v. to the
experimental group (n = 8) 4 times: at 0800 and 1600 h on postnatal days 10 and 11. Control
groups consisted of cannula-implanted, sham-infused litter-mates (n = 3), and of a naive
group (n = 8). A threshold dose of KA (0.2 mg/kg) was administered i.p. to all groups at
0800 h on postnatal day 12. The latency to onset of automatisms and motor seizures and the
duration of both were determined [9,12].
2.7. Experiment VI—effect of CRH and the CRH antagonist on the acquisition of rapid
amygdala kindling
The kindling paradigm was modified from Haas et al. [18] as described elsewhere [7].
Briefly, the kindling stimulus consisted of a 3 s train of 60 Hz biphasic 400 µA peak-to-peak
current, generated by an isolated pulse stimulator (A-M model 2100; Everett, WA) and
visualized using a Tektronix 5111a oscilloscope. Baseline EEGs were recorded for 5 min.
Following each stimulus, EEG was recorded for 1–2 min. Pups were stimulated at 15 min
intervals [7]. Since infant rats (7–12 days) displayed a unique sequence of kindling-induced
behaviors, a kindling scale was generated for them, based on the one defined by Haas et al.
for older pups [18] (Table 1). The rate of kindling development was assessed by measuring
afterdischarge (AD) duration after each stimulation and by the number of stimulations
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needed for the achievement of each kindling stage. Rats aged 10 days were infused with the
CRH antagonist 15–20 min prior to initiation of kindling. The time of administration and the
dose were appropriate for blocking CRH receptors as determined by prevention of CRH-
induced seizures [10].
2.8. Data analysis
All statistical analyses were performed using Prism GraphPad (San Diego, CA). All values
are given as means as ± S.E.M. Results were analyzed for statistical significance (p < 0.05)
using a one-way analysis of variance (ANOVA), student’s t test, or the non-parametric
Mann–Whitney U test, as appropriate.
3. Results
3.1. Glutamate receptor antagonists alter motor but not EEG features of CRH-induced
seizures
Both the competitive and non-competitive antagonists of the NMDA-type glutamate
receptor altered parameters of CRH-induced seizures. Fig. 1 demonstrates that (+)MK-801
tended to increase the latency to the onset of the limbic automatisms induced by CRH, and
also shortened seizure duration (CRH + MK-801: 93.2 ± 39 min; CRH alone: 190 ± 10 min;
p < 0.05). Table 2 demonstrates a dose-dependent effect of CGP-39551 on the latency and
duration of CRH-induced seizures.
However, the inhibitory effects of the glutamate receptor blockers on CRH-induced
behavioral seizures were not due to direct interaction with CRH at the site of origin of the
electrophysiological seizure manifestations: EEGs recorded from the dorsal hippocampus of
pups pretreated with CGP-39551 prior to CRH administration revealed persistent
epileptiform discharges produced by CRH administration (Fig. 2). Thus, while motor
seizures produced by CRH were attenuated, likely by blocking the actions of endogenous
glutamate on motor-neuron control, the epileptic EEG discharges induced by CRH were not
inhibited. EEGs from pups given (+)MK-801 were quite abnormal (data not shown),
consistent with abnormal behaviors and previous reports in the literature [24,40]. Therefore,
the EEGs were not useful for examination of the effects of this agent on CRH-induced EEG
changes.
3.2. Threshold dose and EEG characterization of KA seizures in the infant rat
KA, probably via activation of several ionotropic glutamate receptor types, leads to neuronal
excitation and seizures in both the mature and developing brain. CRH administration leads
to seizures primarily during development, via a mechanism requiring activation of CRH
receptors. However, we tested the hypothesis that CRH mediated excitation utilized the
‘universal’ excitatory means of glutamate receptor activation. More specifically, to examine
potential interactions between the excitatory actions of CRH and of KA, the threshold
convulsant dose of the latter was established for 10–12 day old pups. As is evident from
Table 3, a dose of 0.2 mg/kg led to short bouts of limbic automatisms and behavioral
seizures in 6 of 8 rats, with a long latency. As KA doses increased, latency to onset of
seizures decreased, and the duration of behavioral phenomena lengthened. To ascertain the
epileptic nature of the observed KA-induced behaviors, EEGs were recorded from four 10-
day-old rats injected i.p. with 1 mg/kg KA. Fig. 3 demonstrates bipolar cortical and dorsal
hippocampal recordings from these pups 55–60 min after KA administration. While cortical
leads (top tracings) consist of low-voltage non-rhythmic activity, hippocampal leads (bottom
tracings) reveal spike, poly-spike and rhythmic epileptiform discharges. During these
recordings, animals were either motionless, in a ‘trance-like’ state (B,D), or displayed oral
and motor automatisms (A,C).
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3.3. Interaction of CRH with KA
To examine for a potential synergistic interaction between CRH and KA, threshold doses of
both agents were co-administered to infant rats. The threshold dose of KA (0.2 mg/kg),
Table 3, and the threshold dose of CRH (chosen based on previously published findings [8])
were utilized. Table 4 demonstrates a complex interaction between the two agents: addition
of CRH to threshold KA doses increased the duration and severity of seizures, but the
duration of seizures produced by the combined treatment was not longer than when CRH
was given alone. Behavioral manifestations of these seizures, however, were more severe
with the combined treatment. Overall, these findings are consistent with either an additive or
synergistic interaction of KA and CRH.
3.4. Effects of CRH antagonists on KA seizures
KA in moderate age-specific doses (1 mg/kg) produced consistent and reproducible limbic
seizures when administered to infant rats. The latency to the onset of limbic automatisms
averaged 20 min (Table 5), and seizure duration over the following 180 min was 145.7 ±
11.2 min. Pre-treatment with the CRH antagonist did not modify any qualitative (i.e.,
spectrum of behaviors) or quantitative parameters (latency and duration) of these seizures.
EEG recordings from dorsal hippocampus (Fig. 4B) showed no suppression of the KA-
induced seizures. A second experiment, in which a lower, threshold dose of KA was used
(0.25 mg/kg) also did not reveal any attenuation of the seizures induced by this convulsant
after CRH-antagonist administration (data not shown). The same dose of antagonist was
clearly adequate for attenuation of seizures induced by CRH itself (Table 5).
3.5. Effects of repeated CRH administration on the threshold to KA
Based on evidence that repeated CRH administration has a dose-dependent excitotoxic
effect on amygdala and hippocampal neurons [9], the peptide was given four times to infant
rats, and KA threshold tested 16 h following the last dose. Under these conditions, a
dramatic enhancement of the convulsant potency of KA was observed (Table 6). The
duration and the severity of limbic seizures induced by 0.2 mg/kg of the drug in rats treated
chronically with CRH were equivalent to the effects of a 1.0 mg/kg dose, yielding an
effective five-fold enhancement of KA potency. No spontaneous seizures were noted in the
CRH-treated pups prior to KA administration. The pups that had received four doses of
CRH were not moribund and engaged in age-appropriate behaviors including suckling.
3.6. Effect of CRH antagonist on kindling acquisition
To examine the potential role of CRH in the acquisition of kindling, rats were injected with
the CRH antagonist (9–41)-α-helical CRH prior to onset of kindling. No significant
difference was observed for the number of cycles prior to AD onset between rat pups
pretreated with CRH antagonist (4.0 ± 0.63) and pups that received vehicle (3.2 ± 0.2; Fig.
5A). There was also no significant difference between CRH- (5.0 ± 1.2) and vehicle- (4.8 ±
1.6) treated pups in the number of kindling cycles needed to achieve stage 3 seizures (Fig.
5B). As with the KA-induced seizures, the dose of CRH antagonist chosen was sufficient to
block seizures induced by CRH.
4. Discussion
The major findings of this study are that CRH induces behavioral and electrographic in vivo
limbic seizures via mechanisms that are independent from activation of the ionotropic
glutamate receptors. In addition, CRH-dependent excitatory actions do not play a significant
role in in vivo glutamate-receptor-mediated seizure paradigms such as those related to
kindling and KA administration. However, chronic CRH administration leads to an excitable
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state which heightens the proconvulsant potency of glutamate-receptor activators such as
KA.
The excitatory effects of CRH have been demonstrated in several species, using both in vivo
[10,15,31] and in vitro methods [2,21,39]. In the adult rat, Ehlers [15] described the long
latency (hours) to the onset of seizures induced by CRH. Additionally, a single
administration of CRH produced a sequence of behaviors similar to the behavioral stages of
kindling [15,46]. Therefore, it was hypothesized that CRH could be a kindling stimulus for
the development of limbic seizures [46,47]. Weiss et al. [47], using mature male Sprague–
Dawley rats, studied the effect of CRH on the development of kindling. Pre-administration
of CRH significantly accelerated the development of stage 3 seizures (after 8.2 stimulations
versus 16.1 in vehicle-treated rats). AD duration throughout the kindling process was
significantly longer in CRH pre-treated rats. The data were interpreted to suggest a role for
endogenous CRH in limbic excitability, and a mechanistic interaction with the kindling
process.
The acquisition or development of kindling is generally considered to depend on activation
of NMDA receptors [33]. For example, Holmes et al. [25] have demonstrated that the
selective NMDA receptor blockers 2-amino-phosphonovalerate (APV) and
carboxypiperazine-phosphate (CPP) blocked the development of the kindled state. These
agents had only small depressant effects on seizure expression in fully kindled rats.
Conversely, selective blockers of the AMPA receptor attenuated the expression of seizures
in previously kindled adult rats [32]. Thus, NMDA receptor activation is the major
mechanism for kindling acquisition while expression of kindled seizures depends mainly on
AMPA receptor function. Therefore, the acceleration of kindling acquisition in adult rats by
CRH may indicate an interaction with NMDA receptor activation.
In the infant rat rapid kindling paradigm [7,18], the current study did not suggest a robust
effect of CRH-mediated neurotransmission on the acquisition or the maintenance of the
kindled state. The lack of significant effect of CRH or its antagonist on acquisition of
kindling provides evidence for the NMDA type glutamate-receptor independent mechanism
of action of CRH. Furthermore, the lack of effect on expression of kindling suggests a
mechanism for CRH-mediated excitation that is independent of AMPA receptors as well.
The absence of significant interaction of CRH-mediated excitation with the kindling process
is consistent also with the rapid onset of CRH-induced seizures in the infant rat (Table 5). In
addition to producing seizures very rapidly, CRH has a much higher proconvulsant potency
during the first two postnatal weeks in the rat, as compared with the adult [10]. Seizures
occur with doses 200-fold lower than in adults (7.5 × 10−12 mole for infants vs. 1500 ×
10−12 mole for adults) and are quite protracted [4]. The reason for this enhanced potency of
CRH can be attributed, at least in part, to the high levels of CRH receptors in target limbic
structures during this age [3,26]. Messenger RNA levels for the first member of the CRH
receptor family, CRF1, peak in the amygdala on postnatal day 9, and in the hippocampus on
postnatal day 6 [3]. We, and others, have shown that seizures produced by CRH are
abolished by treatment with competitive CRH receptor antagonists [10]. More recently,
CRF1 has been demonstrated to mediate the proconvulsant effects of CRH in vivo [4].
Potential interactions of CRH with glutamate-receptor mediated excitation and
excitotoxicity have been postulated based on other lines of evidence as well. For example,
excitotoxic cell death is generally considered a glutamate-mediated effect, and pretreatment
with CRH antagonists has been shown to attenuate excitotoxic cell death induced by direct
activation of glutamate receptors [41], ischemia [29,41], or by status epilepticus [30].
Moreover, the ability of CRH to cause selective injury of immature hippocampal and
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amygdala neurons has been demonstrated [9]. However, the findings of the current study do
not support a direct interaction between excitation and excitotoxicity induced by glutamate
receptor activation and the actions of CRH.
The current study has established that blocking of CRH receptors does not attenuate KA-
induced seizures. As is evident from Fig. 3, KA administration to immature rats results in
limbic seizures with epileptiform discharges in the hippocampus, but not in the cortex,
consistent with several previous studies on KA-induced seizures in infant rats [1,23].
Cherubini et al. [13] demonstrated apparent cortical discharges after KA administration to
neonatal rats, but the true origin of the EEG discharges is difficult to ascertain [6]. Fig. 4
documents that administration of CRH antagonists either prior to, or following, KA injection
does not alter the epileptiform EEG activity produced by KA. Thus, although the behavioral
(Table 1) and electrographic seizures produced by CRH and glutamate receptor activation
are quite similar, no evidence for direct interaction between these excitatory processes has
been demonstrated in this study. Since KA-induced seizures are considered to involve
activation of both NMDA and non-NMDA receptors [16,44], the failure of the CRH
antagonist to attenuate these seizures suggests a lack of interaction between CRH and either
of these types of glutamate receptors in this paradigm.
The current study also documented that NMDA receptor antagonists do not alter the
electrographic seizures induced by CRH. Interestingly, the motor correlates of these seizures
were abolished by blocking NMDA receptors. These findings may be interpreted to suggest
that the antagonists may reach motor regions in sufficient concentrations to block behavioral
seizures, yet may not reach limbic regions (e.g., amygdala and hippocampus) in levels which
block the EEG correlates of CRH induced seizures. Contrary to this argument, MK-801 has
been demonstrated to have profound effects on learning and memory in concentrations
which do not affect motor activity appreciably [48]. Taken together, these findings suggest
that excitation induced by CRH, at least as evidenced by in vivo seizures, may be additive to
glutamate actions, but not directly related to them.
In both the developing and the mature CNS, glutamate, via activation mainly of ionotropic
receptors, is the major excitatory neurotransmitter [36]. The role of glutamate receptor
activation in hypoxic seizures during development has been established [27]. A potential
role for NMDA-type glutamate receptor activation in febrile seizures has been postulated
[34]. A number of distinctive properties of glutamate-mediated neurotransmission in the
developing CNS have been described, which may account for increased proconvulsant
potency of this agent in the immature brain. For example, increased levels of glutamate
receptors in the limbic system, unique subunit distribution, splicing variants which permit
increased calcium entry have all been documented in the developing brain [22]. However,
the incidence of spontaneous seizures during development is not increased [5]. It is the
susceptibility to seizures in response to pharmacological convulsants and stressful
circumstances (fever, hypoxia), which is increased during this period [5,22,38]. Since these
insults and stressors induce CRH release in a number of limbic brain regions [17], potential
interaction of glutamate, an excitatory neurotransmitter during both early and adult life, with
CRH, a proconvulsant with maximal potency during development, may account for the
profile of seizure susceptibility observed in the immature human and rat.
The current study established that repeated administration of CRH leads to dramatic
reduction in the convulsant threshold to KA. This phenomenon was evident 14–16 h after
the last of four doses of CRH, each of which led to limbic status epilepticus lasting 4–6 h
[9]. We have previously shown that a number of stressful conditions alter CRH levels in the
hypothalamus, and have recently demonstrated increased amygdala levels of CRH in
stressed neonatal rats [19]. Taken together, these findings suggest that stressful stimuli may
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lead to increased CRH levels in key limbic structures (e.g., amygdala and hippocampus),
and that repeated activation of CRH receptors may alter excitability in these structures.
Hollrigel et al. [21] showed that in vitro application of CRH (0.15 µM) to hippocampal
slices leads to hyperexcitability in CA3 pyramidal neurons, which can result in a net
increase of glutamate release. It is conceded that direct comparison of exogenously
administered and endogenously released CRH is difficult, due to the fact that microdialysis
measurements of CRH in specific brain regions of the immature rat are technically daunting.
In addition, determination of the actual portion of exogenous CRH that reaches the synaptic
cleft is not possible. However, based on the effects of synthetic application, it is proposed
that glutamate receptor activation under circumstances of increased CRH levels may lead to
marked enhancement of the susceptibility to seizures. Thus, after stressors such as fever,
trauma or hypoxia, CRH-mediated excitation may play a role in the sensitization of the
developing brain to glutamatergic proconvulsant effects.
In conclusion, the significance of CRH as an excitatory neuromodulator may derive from the
fact that CRH levels in limbic regions may be increased under conditions that promote
seizures. The human infant and young child commonly develop seizures with onset of
stressful circumstances such as fever [11], trauma [20], or hypoxia [27]. It is proposed that
stress-induced rapid CRH release may be involved in these types of seizures. CRH would
not be expected to contribute significantly to adult seizures, since the latency of CRH-
induced seizures in the adult is much longer (hours), consistent with a reduction of receptor
abundance in the adult amygdala and hippocampus. However in the developing brain,
improvement in the understanding of CRH as an excitatory neuromodulator in the
developing brain may provide a basis for developing pharmacological agents that are more
efficient in treating age-specific seizures in the developing human.
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Fig. 1.
Effect of (+)MK-801 on CRH-induced seizures. The non-competitive NMDA antagonist
(+)MK-801 (0.2 mg/kg) was administered intraperitoneally to 10 day old rats 15 min prior to
intracerebroventricular infusion of CRH (150 × 10−12 mole). Latency to onset of oral
automatisms (A) and duration of behavioral seizures (B) were recorded. All values are
means ± S.E.M. *Indicates statistical significance (p < 0.05; Student’s t-test). CRH =
corticotropin releasing hormone.
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Fig. 2.
Effect of CGP-39551 on epileptic discharges induced by CRH. The tracings depict bipolar
dorsal hippocampal recordings from 10 day old rats. (A) Baseline recordings 5 min prior to
corticotropin releasing hormone (CRH) administration. (B) 40 min after intraperitoneal
injection of the competitive NMDA antagonist CGP-39551 (10 mg/kg). (C) 20 min after
intracerebroventricular (i.c.v.) infusion of CRH (150 × 10−12 mole). (D) Epileptiform
discharges recorded 60 min following CRH administration in a rat pretreated with
CGP-39551 (10 mg/kg) 40 min prior to i.c.v. infusion of CRH (150 × 10−12 mole) to permit
absorption. Horizontal bar = 1 s; Vertical bar = 50 µV.
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Fig. 3.
Effect of KA-induced seizures on EEG recordings. Bipolar cortical (top tracing) and
hippocampal (bottom tracing) recordings in four 10 day old rats. Recordings were obtained
55–60 min after intraperitoneal administration of 1 mg/kg kainic acid (KA). Cortical
recordings consist of low-voltage non-rhythmic activity while hippocampal leads show
rhythmic epileptiform discharges. Behaviorally, animals A,C displayed oral and motor
automatisms(*) and animals B,D were motionless, in a ‘trance-like’ state. Horizontal bar = 1
s; Vertical bar = 50 µV.
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Fig. 4.
Effect of CRH antagonist on epileptic discharge of KA-induced seizures. The tracings
represent bipolar dorsal hippocampal recordings from two 13-day-old rats. (A) Baseline
recordings 3 min prior to kainic acid (KA) and corticotropin releasing hormone (CRH)
antagonist administration show non-rhythmic, low-voltage activity. Note the motion artifact
(arrow) (B) 45–50 min after administration of KA (1 mg/kg) and CRH antagonist (1320 ×
10−12 mole). Rat #1 received KA intraperitoneally (i.p.) 20 min prior to
intracerebroventricular (i.c.v.) infusion of CRH antagonist, and rat #2 received i.c.v.
infusion of CRH antagonist 20 min prior to i.p. injection of KA. Hippocampal leads from
both animals show rhythmic epileptiform discharges (arrows). Horizontal bar = 1 s; Vertical
bar = 50 µV.
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Fig. 5.
Effect of CRH antagonist on the acquisition of kindling. Prior to kindling, corticotropin
releasing hormone (CRH) antagonist (1320 × 10−12 mole) or vehicle were given via
intracerebroventricular infusion to infant rats. Number of kindling cycles to after discharge
onset (A) and number of cycles to stage 3 seizure activity (B) were noted in each group. All
values are means ± S.E.M. No statistically significant difference (p > 0.05; One-way
analysis of variance) was detected between experimental and control groups for either
parameter.
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Table 1
Grading of KA-, CRH- and kindling-induced behaviors in infant rats
Stage Kindling CRH seizures KA seizures
Behavior Behavior Behavior
0 behavior arrest – behavior arrest
1 head bob, facial movement jaw myoclonus scratch, groom
2 ‘chewing’/neck flexion licking, chewing constant chew
3 unilateral clonus forepaw clonus clonus, tonic tail
3.5 alternating clonus ‘swimming’, WDS WDS, alt. clonus
4 limb rotation, bilateral clonus – bilateral clonus
5 loss of balance, extension loss of balance loss of balance
The stages for kindling are modified from [7]; CRH- and KA-induced behaviors were based on observations in > 400 and 80 pups, respectively [8–
10,12] and on unpublished observations. CRH = corticotropin releasing hormone; KA = kainic acid; WD = wet dog shakes; alt = alternating.
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Table 2
Lack of effect of CGP-39551 on the behavioral manifestations of CRH-induced seizures
Treatment N Latency (min) Duration (min)
CRH (150 × 10−12 mole) 16 10.1± 2.0 140.3 ± 13.0
CRH + CGP (30 mg/kg) 9 No seizuresa No seizures
CRH + CGP (15 mg/kg) 3 15, No seizures (2/3)b 5, No seizures (2/3)b
CRH + CGP (10 mg/kg) 3 6.6±2.8 14.0±1.60
CRH + CGP (3 mg/kg) 3 10.3±1.2 58.3±4.0
a
Abnormal behavior.
b
A single animal had seizures with a latency of 15 min. Two others did not have seizures.
Dose effect of administration of the competitive NMDA antagonist CGP-39551 (10 mg/kg) 40 min prior to infusion of CRH (150 × 10−12 mole)
into the lateral cerebral ventricle of infant rats. Duration and latency to onset of limbic automatisms following infusion of CRH were monitored.
All values are means ± S.E.M. CRH = corticotropin releasing hormone.
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Table 3
Determination of threshold convulsant dose of KA in the 10 day old rat
Dose (mg/kg) N Latency (min) Duration (min)
0.2 8 72.1 ± 5.5a   18.8 ± 3.2a
0.3 12 28.1 ± 2.5   43.3 ± 10.6
0.8 3 23.0 ± 0.6 120.0 ± 2.8
1.0 8 20.6 ± 3.3 160.2 ± 3.2
a
Only 6 of 8 rats had seizures.
KA was administered intraperitoneally to infant rats, while controls (n = 8) received equal volumes of vehicle, to determine a threshold dose.
Latency to the onset of limbic automatisms and the duration of seizures were recorded. All values are means ± S.E.M. KA = kainic acid.
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Table 4
Interaction of threshold doses of CRH and KA
Treatment N Seizure duration
(min)
Behavioral features
KA 8 28.1 ± 3.8a oral automatisms, groom, scratch
CRH + KA 9 63.7 ± 8.2 WDS, severe automatisms
CRH 8 62.5 ± 6.0 oral automatisms, rare WDS
Ten day old rat pups were given KA (0.2 mg/kg) intraperitoneally alone or followed 30 min later by intracerebroventricular infusion of 22.5–30 ×
10−12 mole of CRH (see Section 2). A third group received CRH only. Control groups carrying cannula alone or receiving vehicle only did not
have any abnormal behavior.
a
Indicates significant difference from the other two groups (p < 0.05) determined by one-way ANOVA analysis.
CRH = corticotropin releasing hormone; KA = kainic acid; WD = wet dog shakes.
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Table 5
Effect of CRH antagonists on KA induced seizures
Treatment N Latency (min) Duration (min)
KA 8 20.6 ± 3.3 160.2 ± 3.2
CRH antagonist + KA 14 20.0 ± 6.7 145.7 ± 11.2
CRH 11 7.1 ± 0.8 108.5 ± 13.5
CRH + CRH antagonist 12 21.4 ± 4.4a   52.2 ± 14.4a
a
Only 8 of 12 rats had seizures.
The CRH antagonist, (9–41)-α-helical CRH (1320 × 10−12 mole), or vehicle, were administered by intracerebroventricular infusion 15–20 min
prior to the intraperitoneal injection of KA. KA dose (1 mg/kg) was determined to be a moderate one for the infant rat. An additional group of five
animals received the CRH antagonist alone, and did not display behavioral abnormalities. The experimental (KA) and the control groups (KA +
CRH antagonist) do not statistically differ in the latency to or the duration of kainic acid induced seizures (p > 0.05). CRH antagonist does block or
significantly suppress CRH-induced seizures (p < 0.05; Student’s t-test). CRH = corticotropin releasing hormone; KA = kainic acid.
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